235 related articles for article (PubMed ID: 26974491)
1. A direct thrombin inhibitor suppresses protein C activation and factor Va degradation in human plasma: Possible mechanisms of paradoxical enhancement of thrombin generation.
Kamisato C; Furugohri T; Morishima Y
Thromb Res; 2016 May; 141():77-83. PubMed ID: 26974491
[TBL] [Abstract][Full Text] [Related]
2. Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system.
Furugohri T; Sugiyama N; Morishima Y; Shibano T
Thromb Haemost; 2011 Dec; 106(6):1076-83. PubMed ID: 22012070
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin.
Furugohri T; Morishima Y
Thromb Res; 2015 Sep; 136(3):658-62. PubMed ID: 26188924
[TBL] [Abstract][Full Text] [Related]
4. Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.
Perzborn E; Heitmeier S; Buetehorn U; Laux V
J Thromb Haemost; 2014 Jul; 12(7):1054-65. PubMed ID: 24766850
[TBL] [Abstract][Full Text] [Related]
5. Prolongation of clot lysis time by a direct thrombin inhibitor melagatran mediated by paradoxical enhancement of thrombin generation: comparison with a direct factor Xa inhibitor edoxaban.
Morishima Y; Kamisato C; Honda Y
Blood Coagul Fibrinolysis; 2021 Apr; 32(3):209-215. PubMed ID: 33560005
[TBL] [Abstract][Full Text] [Related]
6. Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats.
Furugohri T; Fukuda T; Tsuji N; Kita A; Morishima Y; Shibano T
Eur J Pharmacol; 2012 Jul; 686(1-3):74-80. PubMed ID: 22546231
[TBL] [Abstract][Full Text] [Related]
7. Covalent antithrombin-heparin effect on thrombin-thrombomodulin and activated protein C reaction with factor V/Va.
Van Walderveen MC; Berry LR; Atkinson HM; Chan AK
Thromb Haemost; 2010 May; 103(5):910-9. PubMed ID: 20216984
[TBL] [Abstract][Full Text] [Related]
8. Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C.
Yegneswaran S; Nguyen PM; Gale AJ; Griffin JH
Thromb Haemost; 2009 Jan; 101(1):55-61. PubMed ID: 19132189
[TBL] [Abstract][Full Text] [Related]
9. Importance of individual activated protein C cleavage site regions in coagulation factor V for factor Va inactivation and for factor Xa activation.
Heeb MJ; Rehemtulla A; Moussalli M; Kojima Y; Kaufman RJ
Eur J Biochem; 1999 Feb; 260(1):64-75. PubMed ID: 10091585
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
Konishi N; Hiroe K; Kawamura M
Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
[TBL] [Abstract][Full Text] [Related]
11. The roles of factor Va and protein S in formation of the activated protein C/protein S/factor Va inactivation complex.
Gierula M; Salles-Crawley II; Santamaria S; Teraz-Orosz A; Crawley JTB; Lane DA; Ahnström J
J Thromb Haemost; 2019 Dec; 17(12):2056-2068. PubMed ID: 31364267
[TBL] [Abstract][Full Text] [Related]
12. The Gla26 residue of protein C is required for the binding of protein C to thrombomodulin and endothelial cell protein C receptor, but not to protein S and factor Va.
Nishioka J; Ido M; Hayashi T; Suzuki K
Thromb Haemost; 1996 Feb; 75(2):275-82. PubMed ID: 8815576
[TBL] [Abstract][Full Text] [Related]
13. The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation.
Incampo F; Carrieri C; Semeraro N; Colucci M
Thromb Res; 2014 Nov; 134(5):1110-6. PubMed ID: 25193406
[TBL] [Abstract][Full Text] [Related]
14. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
[TBL] [Abstract][Full Text] [Related]
15. Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro.
Mattsson C; Menschik-Lundin A; Nylander S; Gyzander E; Deinum J
Thromb Res; 2001 Dec; 104(6):475-86. PubMed ID: 11755958
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulant action of melagatran: a comparison between neonates and adults using calibrated automated thrombography (CAT).
Cvirn G; Cimenti C; Kutschera J; Ferstl U; Wagner T; Muntean W; Jurgens G; Gallistl S; Koestenberger M
Eur J Pediatr; 2007 May; 166(5):427-31. PubMed ID: 17047995
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats.
Shirasaki Y; Morishima Y; Shibano T
Thromb Res; 2014 Apr; 133(4):622-8. PubMed ID: 23932349
[TBL] [Abstract][Full Text] [Related]
18. A new regulatory function of activated factor V: inhibition of the activation by tissue factor/factor VII(a) of factor X.
Al Dieri R; Bloemen S; Kelchtermans H; Wagenvoord R; Hemker HC
J Thromb Haemost; 2013 Mar; 11(3):503-11. PubMed ID: 23294934
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of thrombin-induced feedback activation of factor V: a potential pathway for inhibition of thrombin generation by melagatran.
Boström SL; Dagnelid E; Hansson GF; Ulvinge JC
Blood Coagul Fibrinolysis; 2004 Jan; 15(1):25-30. PubMed ID: 15166940
[TBL] [Abstract][Full Text] [Related]
20. Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C.
Gale AJ; Xu X; Pellequer JL; Getzoff ED; Griffin JH
Protein Sci; 2002 Sep; 11(9):2091-101. PubMed ID: 12192065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
